Anti-Tumor Effects Of Dc-Cik Cell In Combination With Pxt/Ddp Against Ovarian Cancer In Mice

Ovarian cancer is one of the most common gynecological malignant tumors in women. The mortality of epithelial ovarian cancer accounted for the first place in various gynecological tumors. The aim of the present study was to explore the anti-effect of dendritic cell-cytokine induced killer cell (DC-CIK cell) in combination with paclitaxel/cisplatin (PXT/DDP) against ovarian cancer in mouse. We divided 30 mice into 6 groups by the different therapeutic approaches, which was respectively control group (A0), DC-CIK-1 group (A1), DC-CIK-2 group (A2), PXT/DDP group (B0), PXT/DDP+DC-CIK-1 group (B1) and PXT/DDP+ DC-CIK-2 group (B2). Tumor tissues morphological changes were observed by hematoxylin and eosin (HE) staining. The method of Td mediated dUTP nick and labeling (TUNEL) was used to detect apoptosis of tumor cells. Natural kill cells (NK-cells), T lymphocytes (T-cells) and B lymphocytes (B-cells) were examined by flow cytometric analysis. The results showed that DC-CIK cell in combination with PXT/DDP significantly improved tumor morphology and promoted Skov-3 cells apoptosis. The combination therapy remarkably reduced microvessel density (MVD). The protein level of vascular endothelial growth factor (VEGF) was inhibited dramatically in combination therapy groups. NK cells, T cells and B cells were up-regulated significantly. These results suggested that DC-CIK cell in combination with PXT/DDP significantly suppressed the tumor growth through inhibition of angiogenesis, which could significantly improve immune functions by increasing NK cells, T cells and B cells number. It could serve as a new approach for ovarian cancer treatment.